These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 27233106

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012-2016.
    Goldstein M, Krilov LR, Fergie J, McLaurin KK, Wade SW, Diakun D, Lenhart GM, Bloomfield A, Kong AM.
    Am J Perinatol; 2018 Dec; 35(14):1433-1442. PubMed ID: 29920638
    [Abstract] [Full Text] [Related]

  • 4. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
    Kong AM, Krilov LR, Fergie J, Goldstein M, Diakun D, Wade SW, Pavilack M, McLaurin KK.
    Am J Perinatol; 2018 Jan; 35(2):192-200. PubMed ID: 28881376
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29-34 wGA) infants without outpatient palivizumab administration.
    Packnett ER, Winer IH, Oladapo A, Wojdyla M.
    Hum Vaccin Immunother; 2023 Aug; 19(2):2252289. PubMed ID: 37828711
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience.
    Rajah B, Sánchez PJ, Garcia-Maurino C, Leber A, Ramilo O, Mejias A.
    J Pediatr; 2017 Feb; 181():183-188.e1. PubMed ID: 27855996
    [Abstract] [Full Text] [Related]

  • 10. Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and Cost of Respiratory Syncytial Virus Hospitalizations among Preterm Infants.
    Krilov LR, Fergie J, Goldstein M, Brannman L.
    Am J Perinatol; 2020 Jan; 37(2):174-183. PubMed ID: 31430818
    [Abstract] [Full Text] [Related]

  • 11. Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017.
    Fergie J, Goldstein M, Krilov LR, Wade SW, Kong AM, Brannman L.
    Hum Vaccin Immunother; 2021 May 04; 17(5):1536-1545. PubMed ID: 33090914
    [Abstract] [Full Text] [Related]

  • 12. Restricted Palivizumab Recommendations and the Impact on RSV Hospitalizations among Infants Born at > 29 Weeks of Gestational Age: An Italian Multicenter Study.
    Priante E, Tavella E, Girardi E, Militello MA, Mardegan V, Maule MM, Dall'Agnola A, Baraldi E, Manzoni P.
    Am J Perinatol; 2019 Jul 04; 36(S 02):S77-S82. PubMed ID: 31238365
    [Abstract] [Full Text] [Related]

  • 13. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.
    Sanchez-Luna M, Burgos-Pol R, Oyagüez I, Figueras-Aloy J, Sánchez-Solís M, Martinón-Torres F, Carbonell-Estrany X.
    BMC Infect Dis; 2017 Oct 17; 17(1):687. PubMed ID: 29041909
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Seasonal peaks and risk factors of respiratory syncytial virus infections related hospitalization of preterm infants in Taiwan.
    Chi H, Chung CH, Lin YJ, Lin CH.
    PLoS One; 2018 Oct 17; 13(5):e0197410. PubMed ID: 29746578
    [Abstract] [Full Text] [Related]

  • 16. Burden of Severe Respiratory Syncytial Virus Disease Among 33-35 Weeks' Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons.
    Anderson EJ, Carbonell-Estrany X, Blanken M, Lanari M, Sheridan-Pereira M, Rodgers-Gray B, Fullarton J, Rouffiac E, Vo P, Notario G, Campbell F, Paes B.
    Pediatr Infect Dis J; 2017 Feb 17; 36(2):160-167. PubMed ID: 27755464
    [Abstract] [Full Text] [Related]

  • 17. Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.
    Ambrose CS, Anderson EJ, Simões EA, Wu X, Elhefni H, Park CL, Sifakis F, Groothuis JR.
    Pediatr Infect Dis J; 2014 Jun 17; 33(6):576-82. PubMed ID: 24622396
    [Abstract] [Full Text] [Related]

  • 18. Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks' Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study.
    Papenburg J, Defoy I, Massé E, Caouette G, Lebel MH.
    J Pediatric Infect Dis Soc; 2021 Apr 03; 10(3):237-244. PubMed ID: 32530035
    [Abstract] [Full Text] [Related]

  • 19. Respiratory Syncytial Virus Disease: Immunoprophylaxis Policy Review and Public Health Concerns in Preterm and Young Infants.
    Staebler S, Blake S.
    Policy Polit Nurs Pract; 2021 Feb 03; 22(1):41-50. PubMed ID: 33050785
    [Abstract] [Full Text] [Related]

  • 20. Respiratory Syncytial Virus and All-Cause Bronchiolitis Hospitalizations Among Preterm Infants Using the Pediatric Health Information System (PHIS).
    Fergie J, Suh M, Jiang X, Fryzek JP, Gonzales T.
    J Infect Dis; 2022 Apr 01; 225(7):1197-1204. PubMed ID: 32691037
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.